{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=14",
    "query": {
      "condition": "Normal Subjects",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 2506,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T05:34:30.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02961491",
      "title": "Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Pheochromocytoma",
        "Paraganglioma"
      ],
      "interventions": [
        {
          "name": "Ultratrace Iobenguane I131",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Insight Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02961491"
    },
    {
      "nct_id": "NCT02974842",
      "title": "Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "BRCA1 Mutation",
        "BRCA2 Mutation",
        "Atypia Suspicious for Malignancy"
      ],
      "interventions": [
        {
          "name": "MAKO 7",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "nVision Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2016-11-02",
      "completion_date": "2017-09-27",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Walnut Creek, California • Charlottesville, Virginia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974842"
    },
    {
      "nct_id": "NCT07860905",
      "title": "A Study to Test the Repeatability and Reproducibility in Rod Intercept Time Within the AdaptDx Pro in Healthy Subjects With Normal Vision (FlashForward)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "No Disease"
      ],
      "interventions": [
        {
          "name": "AdaptDx Pro",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "AdaptDx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "22 Years to 49 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-09-18",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 1,
      "location_summary": "Silverdale, Washington",
      "locations": [
        {
          "city": "Silverdale",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07860905"
    },
    {
      "nct_id": "NCT02871037",
      "title": "Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy"
      ],
      "interventions": [
        {
          "name": "PF-05221304",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2016-08",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02871037"
    },
    {
      "nct_id": "NCT03895203",
      "title": "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 852,
      "start_date": "2019-04-03",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • San Diego, California • Tustin, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03895203"
    },
    {
      "nct_id": "NCT03662854",
      "title": "Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alopecia"
      ],
      "interventions": [
        {
          "name": "Hair Stimulating Complex (HSC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffered Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Histogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2018-07-02",
      "completion_date": "2021-01-21",
      "has_results": false,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03662854"
    },
    {
      "nct_id": "NCT00863941",
      "title": "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abrika Bupropion 150 mg XL Tablet, single dose",
          "type": "DRUG"
        },
        {
          "name": "Wellbutrin XL® 150 mg Tablet, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 28,
      "start_date": "2004-06",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2010-08-23",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 1,
      "location_summary": "Fort Myers, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00863941"
    },
    {
      "nct_id": "NCT00109005",
      "title": "Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Revlimid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2005-04",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109005"
    },
    {
      "nct_id": "NCT03134222",
      "title": "Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Lanraplenib",
          "type": "DRUG"
        },
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Lanraplenib placebo",
          "type": "DRUG"
        },
        {
          "name": "Filgotinib placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2017-05-24",
      "completion_date": "2019-12-18",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03134222"
    },
    {
      "nct_id": "NCT00369395",
      "title": "A Study of Volociximab in Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "volociximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2006-12",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2012-04-27",
      "last_synced_at": "2026-10-24T05:34:30.984Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369395"
    }
  ]
}